

Protecting the developing brain by 17 β estradiol

Julien Pansiot, Jérôme Mairesse and Olivier Baud

Among estrogen hormones, 17 β -estradiol (17 β E2) is the most potent natural form in circulation in mammals. It is known for its role in fetal development, fertility, sexual dimorphism, bone structure, and also for its role in breast or other hormone-dependent cancers. It has also remarkable effects on several systems including the cardiovascular, immune, and nervous systems [1].

17 β E2 is a lipophilic steroid hormone that can diffuse across the blood-brain barrier. It has been extensively studied as a neuroprotective molecule in several preclinical models of brain damage mimicking stroke, hypoxia, excitotoxicity, inflammation, traumatic injury. The use of both *in vivo* and *in vitro* models has demonstrated that 17 β E2 exerts many actions on all the different cell types populating the developing brain, including notably immature oligodendrocytes, microglia, astrocytes and neurons. In a preclinical model of excitotoxic brain injury developed in rodents, we demonstrate that 17 β E2 exposure significantly reduces lesion size, astrocyte-mediated neuronal cell death and white matter damage mediated by neuroinflammation [2]. These data provide evidence for an *in vivo* neuroprotective effect of 17 β E2 in a rat model mimicking periventricular leukomalacia, a common condition observed in very preterm infants.

In oligodendroglial lineage, 17 β E2 promotes the proliferation of immature oligodendrocytes, their differentiation into myelinating oligodendrocytes and strongly reduces apoptotic cell death in response to noxious insult. 17 β E2 reduces neuro-inflammation, known to disrupt oligodendroglial maturation, by downregulating gene transcription of inflammatory mediators and cytokines including inducible nitric oxide synthase, interleukin-1 β , interleukin-6, TNF- α and reactive oxygen species in microglial cells. More precisely, this hormone can switch microglial cells from a pro-inflammatory phenotype M1 to an anti-inflammatory phenotype M2. Hormonal effect on astroglial cells is also significant [3]. 17 β E2 is involved in astrogliosis by decreasing astrocytic proliferation, glial fibrillary acidic protein and vimentin expression in injured brain. Furthermore, many molecules involved in glial response to brain injury are regulated by 17 β E2: in the astrocytes, several studies showed a decrease of pro-inflammatory cytokines, cyclo-oxygenase 2, nitric oxide, NF- κ B, and aquaporin 4, while some growth factors (TGF α , TGF β 1, TGF β 2, FGF2, GDNF, BDNF, IGF-1) are increased as well as the glutamate transporters (GLT-1,

GLAST). Altogether, these changes lead to a reduction in brain inflammation, excitotoxicity and neuronal cell death.

17 β E2 could induce either direct or indirect actions through cellular crosstalk in brain structures. Some *in vitro* studies have demonstrated that 17 β E2 has a direct protective action on neuronal cell survival. But it has been also proposed that this property could be largely mediated by astrocytes releasing many growth factors and the decreasing extracellular glutamate levels. Estrogen receptors named ER α , ER β play also a key role to mediate these properties. ERs are widely expressed in the brain where they are localized in the neurons and the glial cells. 17 β E2 effects can be mediated by ERs via genomic and non-genomic pathways through ERs. For genomic effects, 17 β E2 passively diffuses through the plasma membrane, binds ERs in the cytoplasm, translocates to the nucleus and binds specific DNA sequences called estrogen response elements to regulate genes encoding pro-survival factors and pro-apoptotic proteins. For non-genomic effects, 17 β E2 acts more rapidly by binding ERs located on the plasma membrane and regulates kinase signaling pathways including MAPK/ERK and PI3K/Akt that are involved in the regulation of transcription factors, nuclease kinases, survival, adhesion, metabolism and cell proliferation.

17 β E2 beneficial effect could be mediated by direct effect on central nervous system or peripheral effects. Studies showed that ER α is mostly involved in neuroprotective central effect of 17 β E2. In particular, signalling through ER α in astrocytes, but not through ER α in neurons, appears essential for the beneficial effects of ER α ligand in experimental autoimmune encephalomyelitis [4]. These findings could have implications for understanding the pathophysiology of sex hormone effects in diverse CNS disorders including developmental brain damages. Nevertheless, it has been shown that the mechanisms involved in the protective effect of 17 β E2 are not always mediated by ERs. It could be observed through membrane G protein-coupled estrogen receptor (GPR30, ER-X) with a faster action after estradiol binding. In addition to the regulation of genes transcription, 17 β E2 enables to mediate also the expression of miRNA which are relevant during neuropathological processes of ischemia or other brain injury [5].

Finally, 17 β E2 could have peripheral actions because ERs are expressed in different organs. Alternatively to 17 β E2, selective estrogen receptor

modulators (SERMs, including tamoxifen, raloxifene that are currently used in clinical practice) could be used to confer neuroprotection with a potent effect on inflammation and astrogliosis, regulation of glutamate transporters and release of neurotrophic factors. SERMs may be promising candidate as neuroprotective therapies, but their added-value in clinical practice for this purpose remains to be demonstrated. In particular, long-lasting effects of $17\beta\text{E}2$ given during perinatal period should be documented considering putative neuro-endocrine and behavioural effects of this hormone on the developing brain.

Olivier Baud: Réanimation et Pédiatrie Néonatales & INSERM U1141, Hôpital Robert Debré, Paris, France

Correspondence to: Olivier Baud, **email** olivier.baud@aphp.fr

Keywords: neuroprotection; myelination; estrogens; developing brain; repair; Neuroscience

Received: January 10, 2017

Published: February 01, 2017

REFERENCES

1. Arevalo, et al. *Biochim Biophys Acta*. 2010; 1800:1106-1112.
2. Pansiot, et al. *Exp Neurol*. 2016; 282:56-65.
3. Johann, et al. *J Steroid Biochem Mol Biol*. 2013; 137:71-81.
4. Spence, et al. *Proc Natl Acad Sci U S A*. 2011; 108:8867-8872.
5. Herzog, et al. *J Steroid Biochem Mol Biol*. 2016.